Moderna (MRNA) free cash flow was -$2.1B in FY2025 (+49% YoY). The tables below show the complete quarterly and annual free cash flow history, sourced from SEC EDGAR 10-K and 10-Q filings.
Annual Free Cash Flow
Fiscal Year
Free Cash Flow
YoY
2025
-$2.1B
+49%
2024
-$4.1B
-6%
2023
-$3.8B
-183%
2022
$4.6B
-66%
2021
$13.3B
+581%
2020
$2.0B
+499%
2019
-$491M
-12%
2018
-$437M
-12%
2017
-$390M
-1261%
2016
$34M
Recent Quarterly Free Cash Flow
Quarter
Free Cash Flow
Q2 2026
-$563M
Q1 2026
-$692M
Q4 2025
$891M
Q3 2025
-$880M
Q2 2025
-$922M
Q1 2025
-$1.2B
Q4 2024
$303M
Q3 2024
-$1.7B
Q2 2024
-$1.5B
Q1 2024
-$1.2B
Q4 2023
$402M
Q3 2023
-$1.7B
Source: MRNA on EDGAR. Data from SEC EDGAR 10-K and 10-Q filings. Updated quarterly.